Cargando…

High-Risk Neuroblastoma: A Surgical Perspective

High-risk neuroblastoma requires multimodal treatment including systemic chemotherapy, surgical resection, radiation therapy, stem cell transplant, and immunotherapy. Surgeons play a vital role in obtaining local control of neuroblastoma and must therefore be knowledgeable about this complex patholo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobson, Jillian C., Clark, Rachael A., Chung, Dai H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955866/ https://www.ncbi.nlm.nih.gov/pubmed/36832517 http://dx.doi.org/10.3390/children10020388

Ejemplares similares

Induction of serine hydroxymethyltransferase 2 promotes tumorigenesis and metastasis in neuroblastoma
por: Clark, Rachael A., et al.
Publicado: (2022)

Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis
por: Jacobson, Jillian C., et al.
Publicado: (2022)

Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastoma
por: Qiao, Jingbo, et al.
Publicado: (2022)

Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells
por: Clark, Rachael A., et al.
Publicado: (2020)

Treatment of High-Risk Neuroblastoma
por: Krystal, Julie, et al.
Publicado: (2023)

Ethnic Disparities in the Management of Pediatric Subcutaneous Abscesses
por: Clark, Rachael A., et al.
Publicado: (2022)

Treatment of high-risk neuroblastoma
por: Sung, Ki Woong
Publicado: (2012)

High-Risk Neuroblastoma Treatment Review
por: Smith, Valeria, et al.
Publicado: (2018)

Advances in the Surgical Treatment of Neuroblastoma
por: Luo, Yan-Bing, et al.
Publicado: (2018)

Monoclonal Antibody Therapies for High Risk Neuroblastoma
por: Furman, Wayne L
Publicado: (2021)

Dual-Targeting AKT2 and ERK in cancer stem-like cells in neuroblastoma
por: Kim, Kwang Woon, et al.
Publicado: (2019)

Neuroblastoma: Tumor Biology and Its Implications for Staging and Treatment
por: Van Arendonk, Kyle J., et al.
Publicado: (2019)

Surgical Approaches to Neuroblastoma: Review of the Operative Techniques
por: Fati, Federica, et al.
Publicado: (2021)

Preclinical Models of Neuroblastoma—Current Status and Perspectives
por: Krawczyk, Ewa, et al.
Publicado: (2023)

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
por: Keyel, Michelle E, et al.
Publicado: (2018)

The genetic landscape of high-risk neuroblastoma
por: Pugh, Trevor J., et al.
Publicado: (2013)

The Evolution of Risk Classification for Neuroblastoma
por: Sokol, Elizabeth, et al.
Publicado: (2019)

Small Molecules Targeting INSM1 for the Treatment of High-Risk Neuroblastoma
por: Lan, Michael S., et al.
Publicado: (2023)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
por: Chan, Godfrey Chi-Fung, et al.
Publicado: (2022)

The Use of Cavitron Ultrasonic Surgical Aspirator for High-Risk Neuroblastoma with Image-Defined Risk Factors in Children
por: Pio, Luca, et al.
Publicado: (2023)

Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications
por: Armideo, Erin, et al.
Publicado: (2017)

Surgical Advances in Paediatric Neuroblastoma
por: Martucciello, Giuseppe
Publicado: (2022)

PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs
por: Vella, Serena, et al.
Publicado: (2016)

Epigenetic Deregulation of MicroRNAs in Rhabdomyosarcoma and Neuroblastoma and Translational Perspectives
por: Romania, Paolo, et al.
Publicado: (2012)

Circulating tumor cells in neuroblastoma: Current status and future perspectives
por: Yang, Ran, et al.
Publicado: (2022)

Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma
por: George, S. L., et al.
Publicado: (2020)

Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review
por: Mora, Jaume
Publicado: (2022)

MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment
por: Bartolucci, Damiano, et al.
Publicado: (2022)

A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment
por: Shim, Jenny, et al.
Publicado: (2021)

Analysis of the risk factor for the poor prognosis of localized neuroblastoma after the surgical
por: Zhou, Kai, et al.
Publicado: (2018)

The Tumor Microenvironment in Neuroblastoma: New Players, New Mechanisms of Interaction and New Perspectives
por: Blavier, Laurence, et al.
Publicado: (2020)

Genetic variation associated with childhood and adult stature and risk of MYCN‐amplified neuroblastoma
por: Semmes, Eleanor C., et al.
Publicado: (2020)

Integrative discovery of treatments for high-risk neuroblastoma
por: Almstedt, Elin, et al.
Publicado: (2020)

Surgical Excision of an Adrenal Neuroblastoma in a Dog
por: Mestrinho, Lisa Alexandra, et al.
Publicado: (2019)

Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?
por: Bellanti, Francesco, et al.
Publicado: (2011)

Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95 % tumour resection suffice?
por: Zwaveling, S., et al.
Publicado: (2012)

Neuroblastoma
por: Pearson, D.
Publicado: (1977)

Role of image-defined risk factors in predicting surgical complications of localized neuroblastoma
por: Liu, Tao, et al.
Publicado: (2020)

Artificial Tumor Microenvironments in Neuroblastoma
por: Quinn, Colin H., et al.
Publicado: (2021)

ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo
por: Yu, Yang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9skkovdejsi35gdd1rnlcudvcc